Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Cite this article
The Antiarrhythmic Effects of Ranolazine
1 Department of Cardiovascular Medicine, William Beaumont Hospital–Oakland University School of Medicine, Rochester, MI
Rev. Cardiovasc. Med. 2009, 10(S1), 38–45; https://doi.org/10.3909/ricm10S10006
Published: 20 January 2009
The genesis of cardiac arrhythmia can be grouped into 3 common mechanisms: abnormal automaticity, triggered activity, and re-entry. Alteration of automaticity, triggered activity, conduction, and/or refractoriness of myocardial tissue by drugs will perturb and often prevent the occurrence of arrhythmias. Ranolazine is a novel agent approved in the United States for antianginal therapy. The potential of ranolazine as an antiarrhythmic drug stems from observation of its ability to modify multiple ionic currents in cardiac cells responsible for generation of the action potential. In contrast to currently available antiarrhythmic drugs, ranolazine is well tolerated and has few side effects. Small clinical trials suggest that ranolazine may have a role in the treatment of patients with non–STelevation acute coronary syndrome, atrial fibrillation, long QT syndromes, and sinus node dysfunction.
Non–ST-elevation acute coronary syndrome